EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-7.88%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
-$29.7M
(-2.7%)
Cap. Flow
+$88.7M
Cap. Flow
% of AUM
8.26%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
349
New
26
Increased
163
Reduced
134
Closed
15
Top Buys
| 1 |
TSMC
TSM
|
+$29.5M |
| 2 |
Grab
GRAB
|
+$28.9M |
| 3 |
Qualcomm
QCOM
|
+$21.2M |
| 4 |
Advanced Micro Devices
AMD
|
+$16.3M |
| 5 |
Sea Limited
SE
|
+$14.7M |
Top Sells
| 1 |
Mercado Libre
MELI
|
+$25.6M |
| 2 |
Meta Platforms (Facebook)
META
|
+$13.4M |
| 3 |
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
|
+$6.5M |
| 4 |
IMAB
I-MAB
IMAB
|
+$1.24M |
| 5 |
ProShares Ultra Gold
UGL
|
+$1.01M |
Sector Composition
| 1 | Consumer Discretionary | 34.29% |
| 2 | Technology | 26.19% |
| 3 | Communication Services | 11.91% |
| 4 | Healthcare | 11.24% |
| 5 | Real Estate | 7.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
FibroGen
FGEN
$45.1M
| $204K | 0.02% |
626
-72
| -10% | -$23.5K |
|
302
Xencor
XNCR
$600M
| $204K | 0.02% |
7,855
-62
| -0.8% | -$1.61K |
|
303
American Tower
AMT
$90.7B
| $202K | 0.02% |
942
+19
| +2% | +$4.07K |
|
304
Centene
CNC
$14.2B
| $201K | 0.02% |
2,578
+177
| +7% | +$13.8K |
|
305
Protagonist Therapeutics
PTGX
$3.5B
| $201K | 0.02% |
23,848
-12,185
| -34% | -$103K |
|
|
MYOV
306
DELISTED
Myovant Sciences Ltd.
MYOV
| $200K | 0.02% |
11,153
-938
| -8% | -$16.8K |
|
|
EQRX
307
DELISTED
EQRx, Inc. Common Stock
EQRX
| $199K | 0.02% |
40,228
+18,353
| +84% | +$90.8K |
|
|
AGEN
308
Agenus
AGEN
$136M
| $197K | 0.02% |
4,885
-864
| -15% | -$34.8K |
|
309
Anavex Life Sciences
AVXL
$803M
| $194K | 0.02% |
18,815
-429
| -2% | -$4.42K |
|
310
Gossamer Bio
GOSS
$605M
| $189K | 0.02% |
15,769
-650
| -4% | -$7.79K |
|
311
Arcturus Therapeutics
ARCT
$484M
| $188K | 0.02% |
12,713
-1,022
| -7% | -$15.1K |
|
312
Coherus Oncology, Inc. Common Stock
CHRS
$159M
| $178K | 0.02% |
18,473
-7,517
| -29% | -$72.4K |
|
313
Sana Biotechnology
SANA
$762M
| $177K | 0.02% |
29,495
-12,957
| -31% | -$77.8K |
|
314
Heron Therapeutics
HRTX
$199M
| $175K | 0.02% |
41,391
-45,190
| -52% | -$191K |
|
|
VXRT
315
DELISTED
Vaxart
VXRT
| $158K | 0.01% |
72,516
+10,902
| +18% | +$23.8K |
|
316
Hewlett Packard
HPE
$31B
| $156K | 0.01% |
13,052
-613
| -4% | -$7.33K |
|
317
Nkarta
NKTX
$151M
| $146K | 0.01% |
+11,085
| New | +$146K |
|
318
Kezar Life Sciences
KZR
$29.4M
| $145K | 0.01% |
+1,682
| New | +$145K |
|
319
Atara Biotherapeutics
ATRA
$85.5M
| $139K | 0.01% |
1,467
+442
| +43% | +$41.9K |
|
320
ImmunityBio
IBRX
$2.28B
| $138K | 0.01% |
+27,804
| New | +$138K |
|
321
Sangamo Therapeutics
SGMO
$158M
| $136K | 0.01% |
27,723
-3,869
| -12% | -$19K |
|
322
Viatris
VTRS
$12.2B
| $133K | 0.01% |
15,557
+4,374
| +39% | +$37.4K |
|
323
Recursion Pharmaceuticals
RXRX
$2.02B
| $126K | 0.01% |
+11,859
| New | +$126K |
|
324
Alector
ALEC
$279M
| $122K | 0.01% |
12,866
-3,506
| -21% | -$33.2K |
|
325
Norwegian Cruise Line
NCLH
$11.1B
| $120K | 0.01% |
10,598
| – | – |
|